Sıkça Sorulan Sorular

What is Guselkumab used for?

A fully human monoclonal antibody that selectively inhibits interleukin-23 by targeting its p19 subunit, used to treat moderate-to-severe plaque psoriasis and psoriatic arthritis. It reduces the inflammatory cascade driven by IL-23 that causes the accelerated skin cell turnover characteristic of psoriasis. Patients typically receive injections every eight weeks after an initial loading phase.

Is Guselkumab an approved drug?

Yes, Guselkumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

• ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2364648. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.